Dare Bioscience Investor Presentation Deck
Innovative women's
health pipeline with
multiple program
milestones anticipated
in 2022.
B
A
BAYER
E
R
License agreement for Daré's
investigational Ovaprene®.
Evotec strategic alliance and
KaNDY acquisition.
Daré: Advancing Products Women Want
3.
4
5 https://www.astellas.com/en/news/9471
6
Every program, if
approved, represents
a potential first-line or
first-in-class product
opportunity.
Pharmaceutical companies will continue to seek new and differentiated
products to supplement their branded women's health offerings
Pfizer
Myovant collaboration to
develop and commercialize
relugolix in oncology and
women's health.
https://www.pfizer.com/news/press-release/press-release-detail/myovant-sciences-and-pfizer-announce-collaboration-develop
https://investor.coopercos.com/news-releases/news-release-details/cooper-companies-completes-acquisition-paragardr-iud-teva
Experienced Board of Directors
and Management Team with
demonstrated success in clinical
and product development,
regulatory affairs, corporate
strategy and financial operations.
1.https://www.businesswire.com Dare Bioscience
2.https://www.businesswire.com KaNDy-Therapeutics-Ltd.; https://media.bayer.com/baynews/baynews.nsf/id/Bayer-and-Evotec-form-new-strategic-alliance-focusing-on-polycystic-ovary-syndrome
https://ir.darebioscience.com/news-releases/news-release-details/organon-enters-global-license-agreement-commercialize-dare
Cooper Companies
Acquired global rights to
PARAGARD®
Intrauterine Device (IUD) from
Teva.
astellas
Acquisition of Ogeda.
7.https://www.organon.com/news/organon-launches-as-new-global-womens-health-company/; Organon acquisition-of-Alydia-Health; https://www.organon.com/news/organon-completes-acquisition-of-forendo; Organon Obseva collaboration:
https://www.organon.com/news/organon-and-cirqle-biomedical-enter-research-collaboration-and-license-agreement-for-investigational-non-hormonal-on-demand-contraceptive-candidate/
Women's health
generating more
interest as evidenced by
transformational
transactions.¹-7
ORGANON
License agreement for Daré's FDA
approved Xaciato.
Acquisition of Alydia Health and
Forendo and license agreements with
ObsEva and Cirqle Biomedical.
Merck spinoff, a new firm focused on
women's health and other drugs with
projected annual revenue of >$6
billion.
12View entire presentation